Kinase News and Research

RSS

PGDx to identify novel kinase targets in collaboration with Blueprint Medicines

Personal Genome Diagnostics Inc., today announced that it will use its proprietary methodologies and expertise in genomic analysis of defined cancer subtypes to identify novel kinase targets in collaboration with Blueprint Medicines.

21 May 2013

Targeting glucagon action: A new frontier for regulating diabetes

For the first time, scientists at the Toronto General Research Institute showed that targeting glucagon action in the brain may be a new frontier for regulating diabetes.

20 May 2013

Galapagos, AbbVie announce extension of GLPG0634 clinical development collaboration

Galapagos NV and AbbVie announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3.

17 May 2013

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar (sorafenib) tablets, Stivarga (regorafenib) tablets and the recently U.S. Food and Drug Administration approved product Xofigo (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology, May 31 – June 4, in Chicago, IL (USA).

16 May 2013

Novel drug may increase the effectiveness of radiation therapy for brain cancer

A novel drug may help increase the effectiveness of radiation therapy for the most deadly form of brain cancer, report scientists at Virginia Commonwealth University Massey Cancer Center. In mouse models of human glioblastoma multiforme (GBM), the new drug helped significantly extend survival when used in combination with radiation therapy.

15 May 2013

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma who have progressed on Nexavar (sorafenib) tablets, an anticancer medicine for the treatment of patients with unresectable HCC.

15 May 2013

Vijay Tiwari from IMB receives Bruno Speck Award from Swiss Foundation of Haematological Research

Dr Vijay Tiwari, a Group Leader at the Institute of Molecular Biology (IMB) in Mainz, has been awarded the Bruno Speck Award by the Swiss Foundation of Haematological Research. The award recognises outstanding work by young scientists in the fields of haematology and stem cell research.

15 May 2013

Implications for manipulating immune response for some inflammatory disorders

Cytokines are molecules produced by immune cells that induce the migration of other cells to sites of infection or injury, promote the production of anti-microbial agents, and signal the production of inflammatory mediators.

14 May 2013

Nutritional supplement may improve survival rates of babies born with heart defects

A common nutritional supplement may be part of the magic in improving the survival rates of babies born with heart defects, researchers report. Carnitine, a compound that helps transport fat inside the cell powerhouse where it can be used for energy production, is currently used for purposes ranging from weight loss to chest pain.

10 May 2013

Headline results of Creabilis' CT327 Phase 2b trial in psoriasis patients announced

Creabilis, a late stage European dermatology company with a focus on chronic pruritus (itch), today announces headline results of its Phase 2b trial with its lead product, CT327, in psoriasis patients.

10 May 2013

Drug resistant brain tumors: an interview with Prof. Mischel, Ludwig Institute for Cancer Research and Prof. Bensinger, University of California

In cancer, mutations in proteins that control cell growth are common, leading to unrestrained cellular proliferation and tumor formation.

9 May 2013

Seven-year quest to understand how breast cancer cells resist treatment

A seven-year quest to understand how breast cancer cells resist treatment with the targeted therapy lapatinib has revealed a previously unknown molecular network that regulates cell death.

8 May 2013

Janssen enrolls patients in expanded access program for mantle cell lymphoma

Janssen Research & Development, LLC (Janssen) today announced patients are now enrolling in a multicenter, open-label expanded access program (EAP) in the United States for the investigational oral Bruton's Tyrosine Kinase (BTK) inhibitor ibrutinib, which is being jointly developed by Janssen and Pharmacyclics, Inc.

7 May 2013

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Kinase inhibitors are molecules that block the activity of kinases. Kinases are a specific class of enzymes. They are extremely important in signal transduction processes in the human body meaning that they actually regulate most of the physiological processes that take place in the body.

7 May 2013

EPAC2 and diabetes: an interview with Dr. Hussain, Johns Hopkins University

EPAC stands for exchange protein activated by cyclic AMP (cAMP). cAMP is an (among many) intracellular messenger molecule. cAMP is generated when certain hormones stimulate a cell by binding to their receptor, which is at the outside surface of the cell.

3 May 2013

Everolimus reverses trastuzumab resistance in early HER-2 positive breast cancer

A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has left researchers contemplating a puzzle.

3 May 2013

Study may help diagnose endometrial cancer and lead to new drug development

Endometrial tumors can be reclassified into distinct subtypes based partly on their genomic makeup and may respond to targeted drugs already being tested in clinical trials, according to a large-scale genomic analysis led by researchers at Memorial Sloan-Kettering Cancer Center and other centers within The Cancer Genome Atlas (TCGA) Research Network.

2 May 2013

Researchers identify genetic mutation linked to a typical form of migraine

A research team led by a Howard Hughes Medical Institute investigator at the University of California, San Francisco has identified a genetic mutation that is strongly associated with a typical form of migraine.

2 May 2013

Study: Blocking certain enzymes in cell may prevent cancer cell division and growth

Blocking certain enzymes in the cell may prevent cancer cell division and growth, according to new findings from researchers at the Graduate School of Biomedical Sciences at the Icahn School of Medicine at Mount Sinai.

26 Apr 2013

Increasing unsustainable prices for leukemia drugs represent larger issue across all cancers

The increasing cost of treatments for chronic myeloid leukemia (CML) in the United States has reached unsustainably high levels and may be leaving many patients under- or untreated because they cannot afford care, according to a Blood Forum article supported by nearly 120 CML experts from more than 15 countries on five continents and published online today in Blood, the Journal of the American Society of Hematology (ASH).

26 Apr 2013

Kinase News and Research

PGDx to identify novel kinase targets in collaboration with Blueprint Medicines

Targeting glucagon action: A new frontier for regulating diabetes

Galapagos, AbbVie announce extension of GLPG0634 clinical development collaboration

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Novel drug may increase the effectiveness of radiation therapy for brain cancer

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Vijay Tiwari from IMB receives Bruno Speck Award from Swiss Foundation of Haematological Research

Implications for manipulating immune response for some inflammatory disorders

Nutritional supplement may improve survival rates of babies born with heart defects

Headline results of Creabilis' CT327 Phase 2b trial in psoriasis patients announced

Drug resistant brain tumors: an interview with Prof. Mischel, Ludwig Institute for Cancer Research and Prof. Bensinger, University of California

Seven-year quest to understand how breast cancer cells resist treatment

Janssen enrolls patients in expanded access program for mantle cell lymphoma

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

EPAC2 and diabetes: an interview with Dr. Hussain, Johns Hopkins University

Everolimus reverses trastuzumab resistance in early HER-2 positive breast cancer

Study may help diagnose endometrial cancer and lead to new drug development

Researchers identify genetic mutation linked to a typical form of migraine

Study: Blocking certain enzymes in cell may prevent cancer cell division and growth

Increasing unsustainable prices for leukemia drugs represent larger issue across all cancers

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News